Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese

被引:8
|
作者
Jiang, Li-Peng [1 ]
Sun, Hong-Zhi [2 ,3 ]
机构
[1] Jinzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Jinzhou, Peoples R China
[2] Jinzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Jinzhou, Peoples R China
[3] Jinzhou Med Univ, Key Lab Liaoning Tumor Clin Metabol KLLTCM, Jinzhou, Peoples R China
来源
关键词
myristic acid (14:0); palmitic acid (16:0); IR; NAFLD; T2D; METABOLIC SYNDROME; PALMITIC ACID; MYRISTIC ACID; EPIDEMIOLOGY; ASSOCIATION; PREVALENCE; NAFLD; LIPOTOXICITY; DIAGNOSIS; PATHOLOGY;
D O I
10.3389/fendo.2022.1051807
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study aimed to explore relationships between long-chain saturated fatty acids (LSFAs) and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2D); and whether insulin action had an interactive effect with LSFAs on NAFLD progression. Methods: From April 2018 to April 2019, we extracted the electronic medical records of 481 patients with T2D who meet the inclusion and exclusion criteria from the Second Affiliated Hospital of Dalian Medical University. Ultrasound was used to estimate NAFLD at admission. Logistic regression analysis were used to estimate odds ratios (OR) and 95% confidence intervals (CI). The additive interaction was carried out to estimate interactions between LSFAs and insulin resistance (IR) in NAFLD patients with T2D. Results: Myristic acid (14:0) and palmitic add (16:0) were positively associated with the risk of NAFLD (OR for myristic acid (14:0): 7.516, 3.557-15.882 and OR for palmitic acid (16:0): 4.071, 1.987-8.343, respectively). After adjustment for traditional risk factors, these associations were slightly attenuated but still highly significant. Co-presence of myristic acid (14:0)>72.83 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 9.691 (4.113-22.833). Similarly, copresence of palmitic acid (16:0)>3745.43 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 6.518(2.860-14.854). However, stearic acid (18:0) and risk of NAFLD have no association. Moreover, there was no association between very-long-chain SFAs (VLSFAs) and risk of NAFLD. Discussion: Myristic acid (14:0) and palmitic acid (16:0) were positively associated with the risk of NAFLD in T2D patients in China. High IR amplified the effect of high myristic acid (14:0) and high palmitic acid (16:0) on NAFLD.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Long chain saturated fatty acids and insulin resistance in aging.
    Hardy, RW
    MecklingGill, KA
    Williford, J
    Wei, HC
    DIABETES, 1997, 46 : 236 - 236
  • [12] Nonalcoholic Fatty Liver Disease Markers Are Associated with Insulin Resistance in Type 1 Diabetes
    Bulum, Tomislav
    Kolaric, Branko
    Duvnjak, Lea
    Duvnjak, Marko
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (12) : 3655 - 3663
  • [13] Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids
    Bouzianas, Dimitrios G.
    Bouziana, Stella D.
    Hatzitolios, Apostolos I.
    NUTRITION REVIEWS, 2013, 71 (11) : 753 - 771
  • [14] Nonalcoholic Fatty Liver Disease Markers Are Associated with Insulin Resistance in Type 1 Diabetes
    Tomislav Bulum
    Branko Kolarić
    Lea Duvnjak
    Marko Duvnjak
    Digestive Diseases and Sciences, 2011, 56 : 3655 - 3663
  • [15] Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease
    Videla, LA
    Rodrigo, R
    Araya, J
    Poniachik, J
    FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (09) : 1499 - 1507
  • [16] The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
    Sheng, Xia
    Che, Hui
    Ji, Qingming
    Yang, Fan
    Lv, Jie
    Wang, Yueqiu
    Xian, Huimin
    Wang, Lihong
    HORMONE AND METABOLIC RESEARCH, 2018, 50 (05) : 397 - 402
  • [17] Insulin Resistance in Nonalcoholic Fatty Liver Disease
    Bugianesi, E.
    Moscatiello, S.
    Ciaravella, M. F.
    Marchesini, G.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1941 - 1951
  • [18] Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes
    Goedeke, Leigh
    Perry, Rachel J.
    Shulman, Gerald I.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59, 2019, 59 : 65 - 87
  • [19] Association of nonalcoholic fatty liver disease with insulin resistance -: Is OGTT indicated in nonalcoholic fatty liver disease?
    Sargin, M
    Uygur-Bayramiçli, O
    Sargin, H
    Orbay, E
    Yayla, A
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 37 (05) : 399 - 402
  • [20] Simple and facilitated diffusion of long chain fatty acids in the pathogenesis of nonalcoholic fatty liver disease
    Berk, Klaudia
    Ilowska, Nicoletta
    Konstantynowicz-Nowicka, Karolina
    Chabowski, Adrian
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2017, 71 : 1177 - 1186